One Ontario University is trying to find an affordable and accessible way to treat COVID-19. \nAn international study lead by McMaster University is now testing three widely available drugs to see if they treat early symptoms of the virus. \nEditor's Choice: Ontario Mansion For Sale Is Made Out Of Silos & Overlooks 'Canada's Prettiest Town'\n\n\n\n“\n\n\nEvidence is quickly emerging that suggests a number of drugs may have a promising effect on reducing COVID-19 disease severity in patients with mild to moderate disease.\n\n\nEdward Mills\n\n\nAccording to a press release, the trials will research the effectiveness of ivermectin, metformin, and fluvoxamine in preventing the virus' progression.\nThe university states that the results of tests could be known in as little as two to three months.\nThe drugs have reportedly garnered "mixed results" in previous studies. However, they have never been tested in a large clinical trial.\nIvermectin, a drug used for treating parasitic infections, has shown "promise" in treating COVID-19 and only costs $5 per treatment. \nThe press release underlines the importance of finding additional treatments in addition to the vaccine, as it is not readily available to everyone. \n\n“As the pandemic continues with no end in sight for many low- and middle-income countries, there is a growing urgency for effective therapies. This could be a real game-changer,” stated Edward Mills, a McMaster professor of health research methods, evidence, and impact.\nNew data recently revealed that Canada’s COVID-19 vaccine distribution is lagging behind other countries.\nThe country is currently ranked 38th for vaccination rates per 100 people.